JP7098629B2 - 抗ｐｄ－１モノクローナル抗体、その製造方法及び用途 - Google Patents

抗ｐｄ－１モノクローナル抗体、その製造方法及び用途 Download PDF

Info

Publication number
JP7098629B2
JP7098629B2 JP2019536981A JP2019536981A JP7098629B2 JP 7098629 B2 JP7098629 B2 JP 7098629B2 JP 2019536981 A JP2019536981 A JP 2019536981A JP 2019536981 A JP2019536981 A JP 2019536981A JP 7098629 B2 JP7098629 B2 JP 7098629B2
Authority
JP
Japan
Prior art keywords
seq
human
monoclonal antibody
represented
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019536981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505017A5 (enExample
JP2020505017A (ja
Inventor
趙▲ジエ▼
高宏海
郭錦林
党尉
朱玲巧
張成海
趙楽
陳建鶴
黄浩旻
朱禎平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Publication of JP2020505017A publication Critical patent/JP2020505017A/ja
Publication of JP2020505017A5 publication Critical patent/JP2020505017A5/ja
Application granted granted Critical
Publication of JP7098629B2 publication Critical patent/JP7098629B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019536981A 2017-01-24 2018-01-22 抗ｐｄ－１モノクローナル抗体、その製造方法及び用途 Active JP7098629B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710054783.5A CN108341871A (zh) 2017-01-24 2017-01-24 抗pd-1单克隆抗体及其制备方法和应用
CN201710054783.5 2017-01-24
PCT/CN2018/073575 WO2018137576A1 (zh) 2017-01-24 2018-01-22 抗pd-1单克隆抗体及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2020505017A JP2020505017A (ja) 2020-02-20
JP2020505017A5 JP2020505017A5 (enExample) 2020-11-19
JP7098629B2 true JP7098629B2 (ja) 2022-07-11

Family

ID=62962821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536981A Active JP7098629B2 (ja) 2017-01-24 2018-01-22 抗ｐｄ－１モノクローナル抗体、その製造方法及び用途

Country Status (5)

Country Link
US (1) US11254746B2 (enExample)
EP (1) EP3575322B1 (enExample)
JP (1) JP7098629B2 (enExample)
CN (2) CN108341871A (enExample)
WO (1) WO2018137576A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111196856A (zh) 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
CN111196855B (zh) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
CN111518206B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN109748965A (zh) * 2019-03-13 2019-05-14 安徽安科生物工程（集团）股份有限公司 全人源pd-l1单克隆抗体及其制备方法和应用
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN110563849B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
US20230002492A1 (en) * 2019-11-08 2023-01-05 Simcere (Shanghai) Pharmaceutical Co., Ltd. Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
LT4157876T (lt) 2020-05-26 2024-10-25 Boehringer Ingelheim International Gmbh Anti-pd-1 antikūnai
CN113754767A (zh) * 2020-06-03 2021-12-07 上海恒润达生生物科技股份有限公司 抗人pd-1抗体及其用途
CN111647624A (zh) * 2020-06-10 2020-09-11 成都和同易创生物科技有限公司 Tsab人源单克隆抗体重组载体、重组抗体及其制备方法
CN113797330A (zh) * 2020-06-11 2021-12-17 三生国健药业（上海）股份有限公司 一种抗pd-1单克隆抗体液体制剂
CN114761434B (zh) * 2020-09-30 2023-06-27 苏州沙砾生物科技有限公司 Pd-1抗体及其制备方法与应用
EP4261225A4 (en) * 2020-12-10 2024-11-13 Eutilex Co., Ltd. ANTI-PD-1 ANTIBODY AND ITS USES
CN114316047B (zh) * 2021-01-14 2023-12-22 东大生物技术(苏州)有限公司 一组pd-1单克隆抗体及其医药用途
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN113150154B (zh) * 2021-04-15 2022-05-10 博奥信生物技术（南京）有限公司 抗人pdl1单克隆抗体及其用途
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
CN114539406B (zh) * 2021-12-31 2023-04-14 浙江大学 一种全人源抗PD-1的单克隆抗体No.8-3及其应用
CN114539407B (zh) * 2021-12-31 2023-04-18 浙江大学 一种全人源抗PD-1的单克隆抗体No.1-10及其应用
JP2025518812A (ja) * 2022-06-01 2025-06-19 シンクロミューン・インコーポレイテッド 腫瘍細胞溶解、及び免疫療法成分の組み合わせの腫瘍内投与によるがんを処置するための方法
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
CN115951055B (zh) * 2022-12-13 2024-10-15 湖南湘医投蕙尧生命科技有限公司 一种癌症相关蛋白及其抗体和应用
WO2025128264A1 (en) * 2023-12-15 2025-06-19 Pharmaessentia Corporation Anti-pd-1 monoclonal antibody and methods of use thereof
CN120518767B (zh) * 2025-05-30 2025-11-11 中国人民解放军军事科学院军事医学研究院 一种pd-1单克隆抗体及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006340714A (ja) 2005-05-09 2006-12-21 Ono Pharmaceut Co Ltd ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2010530753A (ja) 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2015112900A1 (en) 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2016015685A1 (zh) 2014-07-30 2016-02-04 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
JP2016523265A (ja) 2013-06-26 2016-08-08 シャンハイ ジュンシー バイオサイエンスィズ インコーポレイテッド 抗ｐｄ−１抗体およびその応用
CN106008714A (zh) 2016-05-24 2016-10-12 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
WO2017058115A1 (en) 2015-09-29 2017-04-06 Asia Biotech Pte. Ltd. Pd-1 antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2342229A1 (en) * 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
ES2792183T3 (es) * 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
SG11201700496WA (en) * 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
CN105622753B (zh) * 2014-11-04 2019-04-09 博生吉医药科技(苏州)有限公司 一种pd-1单克隆抗体及其应用
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CN106336460B (zh) * 2015-07-15 2021-02-12 杭州贝颐药业有限公司 抗人pd-1蛋白抗体及其编码基因和应用
CN116333138A (zh) * 2015-07-30 2023-06-27 宏观基因有限公司 Pd-1结合分子和其使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006340714A (ja) 2005-05-09 2006-12-21 Ono Pharmaceut Co Ltd ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2010530753A (ja) 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
JP2016523265A (ja) 2013-06-26 2016-08-08 シャンハイ ジュンシー バイオサイエンスィズ インコーポレイテッド 抗ｐｄ−１抗体およびその応用
WO2015112900A1 (en) 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2016015685A1 (zh) 2014-07-30 2016-02-04 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
WO2017058115A1 (en) 2015-09-29 2017-04-06 Asia Biotech Pte. Ltd. Pd-1 antibodies and uses thereof
CN106008714A (zh) 2016-05-24 2016-10-12 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
生物学辞典，第1版，2010年，第600頁

Also Published As

Publication number Publication date
EP3575322A1 (en) 2019-12-04
EP3575322B1 (en) 2024-11-27
CN108341871A (zh) 2018-07-31
WO2018137576A1 (zh) 2018-08-02
US11254746B2 (en) 2022-02-22
CN110225928B (zh) 2021-05-28
CN110225928A (zh) 2019-09-10
EP3575322A4 (en) 2020-12-30
JP2020505017A (ja) 2020-02-20
US20200377597A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
JP7098629B2 (ja) 抗ｐｄ－１モノクローナル抗体、その製造方法及び用途
CN102725309B (zh) 针对GPVI的新的拮抗剂抗体及其Fab片段及其用途
JP7554309B2 (ja) 抗ｃｄ１４７抗体
WO2022105914A1 (zh) Cd70抗体及其应用
JP2024530451A (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
JP7692918B2 (ja) 抗ｌａｇ３モノクローナル抗体、その製造方法および使用
JP7397897B2 (ja) ヒトｐｄ－ｌ１に結合する抗体
JP7681069B2 (ja) 抗ペリオスチン抗体及びその使用
US20250136687A1 (en) Anti-human cd3 antibody and use thereof
US20250346665A1 (en) Anti-cldn18.2 antibody and application thereof
CN116829587A (zh) Her2抗体及其应用
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
US20240018255A1 (en) ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
JP2024012394A (ja) 抗ヒトｔｌｒ７抗体
KR20220119393A (ko) 약학 조성물, 이의 제조 방법 및 이의 용도
WO2021032174A1 (zh) 一种抗cd47抗原结合蛋白及其应用
CN116199777B (zh) 抗hNKG2D抗体及其应用
WO2019072274A1 (zh) 一种激动型4-1bb单克隆抗体
WO2024078558A1 (zh) 抗cd100抗体及其用途
WO2025025190A1 (zh) 抗cd73抗体及其应用
CN121045380A (zh) Cd19结合分子及其用途
JP2024509369A (ja) 抗ｐｄ－ｌ１抗体及びその使用
CN117164719A (zh) 靶向SIRPα和PD-L1的双特异性抗体或其抗原结合片段及应用
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40066221A (zh) 人源化抗vegf fab抗体片段及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220629

R150 Certificate of patent or registration of utility model

Ref document number: 7098629

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250